NEW HAVEN, Conn.--(BUSINESS WIRE)--BioRelix, Inc., a biopharmaceutical company focused on the development of novel anti-infective agents, announced today the completion of a $25.75 million Series A financing. The financing was led by CHL Medical Partners with participation by new investors New Leaf Venture Partners and Aisling Capital and existing investors Novartis Venture Fund, Elm Street Ventures and Alexandria Real Estate Equities. BioRelix expects to use the funds to build a portfolio of anti-infective product candidates based on novel patented bacterial RNA targets, termed RiboSwitches™, which were identified by the laboratory of BioRelix’ co-founder, Ronald Breaker, Ph.D., Howard Hughes Investigator and Henry Ford II Professor at Yale University.
